Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance

2011 ◽  
Vol 126 (1-3) ◽  
pp. 117-123 ◽  
Author(s):  
Karen E. Moeller ◽  
Sally K. Rigler ◽  
Angela Mayorga ◽  
Niaman Nazir ◽  
Theresa I. Shireman
Keyword(s):  
Second Generation ◽  
Metabolic Effects ◽  
Public Insurance ◽  
Second Generation Antipsychotics

scholarly journals Sertindole in the Management of Schizophrenia

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S5729 ◽  
Author(s):  
Mario F. Juruena ◽  
Eduardo Ponde00C9; De Sena ◽  
Irismar Reis De Oliveira
Keyword(s):  
Atypical Antipsychotics ◽  
Second Generation ◽  
Antipsychotic Agents ◽  
Comparable Efficacy ◽  
Psychotic Symptoms ◽  
Alternative Treatment Option ◽  
Second Generation Antipsychotics

Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical antipsychotics sertindole's pharmacology, safety and status, and mainly evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis. In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents. Further clinical studies, mainly comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in the treatment of schizophrenia.

Adherence to Clinical Practice Guidelines When Prescribing Second-Generation Antipsychotics

2016 ◽  
Vol 9 (1) ◽  
pp. 120-123
Author(s):  
Leigh Powers
Keyword(s):  
Quality Of Care ◽  
Second Generation ◽  
Mental Health Center ◽  
Fasting Blood Glucose ◽  
Southeast United States ◽  
Second Generation Antipsychotics ◽  
Study Results ◽  
Effect Monitoring ◽  
Time Point

This study was undertaken to determine adherence rates to side effect monitoring guidelines of second-generation antipsychotics (SGAs) approximately 10 years after their publication to assess the quality of care being provided to patients with mental illness at an urban community mental health center located in the Southeast United States. Results indicated an initial combined collection of fasting blood glucose (FBG) and fasting lipid profile (FLP) of 30%. At the 3-month time point, 20% of FBG and FLP were checked and at 1 year 14%. Study results suggest there is a need for practice improvements to increase quality of care.

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses

2010 ◽  
Vol 12 (2) ◽  
pp. 172-184 ◽  
Author(s):  
Carmen Moreno ◽  
Jessica Merchán-Naranjo ◽  
Mar Álvarez ◽  
Inmaculada Baeza ◽  
Jose A Alda ◽  
...  
Keyword(s):  
Second Generation ◽  
Metabolic Effects ◽  
Second Generation Antipsychotics
Sign in / Sign up

Export Citation Format

Share Document